605199 Hainan Huluwa Pharmaceutical Group
- 15.62
- +1.42+10.00%
Hainan Huluwa Pharmaceutical Group News
Hainan Huluwa Pharmaceutical Group (605199.SH): Zhongjia Rui has cumulatively reduced its shareholding by 1.33%.
Glory Holdings announced on November 27 that hainan huluwa pharmaceutical group (605199.SH) received a notice from Zhongjiao Rui stating that the shareholding plan had been completed. From November 25 to November 26, 2024, Zhongjiao Rui reduced its shareholding by a total of 5,341,050 shares, accounting for 1.33% of the company's total share capital.
The A-share innovative drugs sector surged, hainan huluwa pharmaceutical group reached its maximum increase.
Greelonghui November 26th | Hainan Huluwa pharmaceutical group hit the limit up, Huayu Pharmaceutical rose more than 7%, Sailong Pharmaceutical Group, Betta Pharmaceuticals, Shanghai Allist Pharmaceuticals Co., Ltd., and others followed the upward trend.
Express News | hainan huluwa pharmaceutical group: The company and its subsidiaries have received a total of 10.6863 million yuan in government subsidies related to income.
Hainan Huluwa Pharmaceutical Group (605199.SH): Intends to change some of the raised funds investment projects.
Gelonghui November 11th | hainan huluwa pharmaceutical group (605199.SH) announced that the original 'pediatric pharmaceutical research and development' project includes three pharmaceutical research and development sub-projects: children's Ma Long cough and asthma granules, children's Huaji granules, children's pneumonia patches, etc. It is planned to invest 50 million yuan in the funds raised. As of October 31, 2024, a total of 20.1917 million yuan of the raised funds has been used, and the remaining uninvested raised funds balance is 30.5728 million yuan (including interest). Due to factors such as the relatively large difficulty in recruiting children for clinical trials of pediatric medicines, the research and development progress of the above pharmaceutical research and development projects lags behind the previous expectations.
Express News | Hainan Huluwa Pharmaceutical Group: obtained the registration certificate for oseltamivir phosphate capsules.
hainan huluwa pharmaceutical group (605199.SH) subsidiary guangxi viwei received pharmaceutical GMP compliance inspection results
Hainan Huluwa Pharmaceutical Group (605199.SH) announced that its wholly-owned subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. (hereinafter referred to as...
Hainan Huluwa Pharmaceutical Group (605199.SH) obtained the registration certificate for Acalabrutinib injection pharmaceutical.
Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the company recently received approval issued by the National Medical Products Administration regarding...
Express News | Hainan Huluwa Pharmaceutical Group: Obtained the registration certificate for the injection of Arbidol pharmaceutical.
Express News | Hainan Huluwa Pharmaceutical Group: Shareholder Zhongjiarui plans to reduce its shareholding by no more than 1.34%.
Report for the third quarter of 2024 of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Hainan Huluwa Pharmaceutical Group (605199.SH): The company and its subsidiaries plan to carry out leasing business.
On October 18, Hainan Huluwa Pharmaceutical Group (605199.SH) announced that in order to optimize the financing structure and expand financing channels, the company and its wholly-owned subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. (referred to as "Guangxi Weiwei") intend to use part of the assets and equipment as the transfer target and leased property, to conduct financing leaseback business with China CITIC Financial Leasing Co., Ltd. (referred to as "CITIC Leasing"), with a lease term of 36 months and a total financing amount not exceeding 0.2 billion yuan, starting from the date specified in the relevant financing contract.
Hainan Hainan Huluwa Pharmaceutical Group (605199.SH) plans to increase its capital by 0.29 billion yuan through debt-for-equity swaps with debt-for-equity swaps.
hainan huluwa pharmaceutical group (605199.SH) released an announcement to improve hainan huluwa pharmaceutical co., ltd. (referred to as "hainan huluwa...
Hainan Huluwa Pharmaceutical Group Provides 40-Million-Yuan Guarantee for Subsidiary's Loan
hainan huluwa pharmaceutical group (605199.SH): there is no drug to treat anthrax.
Hainan Huluwa Pharmaceutical Group (605199.SH) stated on the investor interaction platform on September 10th that the company does not have a drug for treating anthrax.
Express News | The Shanghai Stock Exchange has decided to terminate the review of the application for Hainan Huluwa Pharmaceutical Group to issue convertible corporate bonds to unspecified parties.
Hainan Huluwa Pharmaceutical Group Co., Ltd. 2024 Semi-Annual Report
Hainan Huluwa Pharmaceutical Group Co., Ltd. 2024 Semi-Annual Report_Summary
Hainan Huluwa Pharmaceutical Group (605199.SH): The net income in the first half of the year was 78.7516 million yuan, a year-on-year increase of 28.33%.
Hainan Huluwa Pharmaceutical Group (Ticker Symbol: 605199.SH) released its semi-annual report on August 28th. During the reporting period, the company achieved a revenue of 846.7141 million yuan, a decrease of 7.36% year-on-year. The net income attributable to shareholders of the listed company was 78.7516 million yuan, an increase of 28.33% year-on-year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 42.19 million yuan, a decrease of 11.91% year-on-year.
Express News | Hainan Huluwa Pharmaceutical Group: Net income in the first half of 2024 increased by 28.33% year-on-year.
Express News | hainan huluwa pharmaceutical group: obtained the registration certificate for inhaled acetylcysteine solution pharmaceutical.
Analysis
Price Target
No Data
No Data